Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Small Cell Lung Cancer
Advertisement
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The recommendation is based on results from the phase 3 ADRIATIC trial.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.